Myriad Genetics, Inc.’s latest rating changes from various analysts

Myriad Genetics, Inc.’s recently made public that its Chief Financial Officer Riggsbee Richard Bryan unloaded Company’s shares for reported $0.57 million on Dec 01. In the deal valued at $19.09 per share,30,000 shares were sold. As a result of this transaction, Riggsbee Richard Bryan now holds 291,812 shares worth roughly $6.57 million.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Then, Riggsbee Richard Bryan sold 30,000 shares, generating $470,622 in total proceeds. Upon selling the shares at $15.69, the Chief Financial Officer now owns 321,812 shares.

Before that, SPIEGELMAN DANIEL K sold 8,638 shares. Myriad Genetics, Inc. shares valued at $198,760 were divested by the Director at a price of $23.01 per share. As a result of the transaction, SPIEGELMAN DANIEL K now holds 40,493 shares, worth roughly $0.91 million.

Price Performance Review of MYGN

On Tuesday, Myriad Genetics, Inc. [NASDAQ:MYGN] saw its stock fall -0.92% to $22.51. Over the last five days, the stock has gained 5.04%. Myriad Genetics, Inc. shares have risen nearly 17.61% since the year began. Nevertheless, the stocks have risen 10.51% over the past one year. While a 52-week high of $24.21 was reached on 01/29/24, a 52-week low of $13.82 was recorded on 01/08/24. SMA at 50 days reached $19.54, while 200 days put it at $19.29. A total of 0.59 million shares were traded, compared to the trading of 0.49 million shares in the previous session.

Levels Of Support And Resistance For MYGN Stock

The 24-hour chart illustrates a support level at 22.26, which if violated will result in even more drops to 22.01. On the upside, there is a resistance level at 22.74. A further resistance level may holdings at 22.97. The Relative Strength Index (RSI) on the 14-day chart is 70.35, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.56, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 6.56%. Stochastics %K at 94.13% indicates the stock is a selling.

How much short interest is there in Myriad Genetics, Inc.?

A steep rise in short interest was recorded in Myriad Genetics, Inc. stocks on Jan 11, 2024, dropping by -1.18 million shares to a total of 3.82 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2023 was 5.0 million shares. There was a decline of -30.89%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 5.90% of the overall stock float, the days-to-cover ratio (short ratio) fell to 4.93.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular